Deficient SARS-CoV-2 hybrid immunity during inflammatory bowel disease
Copyright © 2024. Published by Elsevier Inc.
| Publié dans: | Clinical immunology (Orlando, Fla.). - 1999. - 271(2024) vom: 05. Dez., Seite 110404 |
|---|---|
| Auteur principal: | |
| Autres auteurs: | , , , , , , , , , , , , , |
| Format: | Article en ligne |
| Langue: | English |
| Publié: |
2024
|
| Accès à la collection: | Clinical immunology (Orlando, Fla.) |
| Sujets: | Journal Article Activation Antibody waning Hybrid immunity IBD Inflammation TNF inhibitors |
| Résumé: | Copyright © 2024. Published by Elsevier Inc. Patients with Inflammatory Bowel Disease (IBD) undergoing immunosuppressive therapies face heightened susceptibility to severe COVID-19. An in-depth understanding of systemic inflammation and cellular immune responses after SARS-CoV-2 vaccination and breakthrough infections (BTI) is required for optimizing vaccine strategies in this population. While the prevalence of high serological responders post- third COVID-19 vaccine dose was lower, and the antibody waning was higher in IBD patients than in healthy donors (HD), IBD patients showed an increase in anti-RBD Wild Type IgG levels and cross-reactive Spike -specific memory B cells following BTI. However, there was no significant enhancement in cellular immune responses against anti-SARS-CoV-2 post-BTI, with responses instead characterized by activation of SARS-CoV-2 specific and also bystander CD8 T cells. These results suggest a complex interaction between chronic inflammation in IBD and the generation of new immune responses, highlighting the need for tailored vaccine regimens and anti-inflammatory therapies to boost cellular immunity against SARS-CoV-2 |
|---|---|
| Description: | Date Revised 11.12.2024 published: Print-Electronic Citation Status Publisher |
| ISSN: | 1521-7035 |
| DOI: | 10.1016/j.clim.2024.110404 |